Shares are up 23% on 1,492 trades today. $2.29 a share on almost 600k volume.
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients
Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCEs Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients
Conference call and webcast to be held today at 8:30 a.m. Eastern Time